The contract from the National Institute of Allergy and Infectious Diseases is for $10.2 million over five years and supports establishment and operation of a Population Genetics Analysis Program. The programs would investigate immune-response gene polymorphisms that affect an individual's susceptibility to infection, as well as their response to vaccination. Researchers also will study potential cellular and hormonal responses to smallpox vaccination.
Dr. Poland says Mayo Clinic's research expertise was a factor in the NIAID decision. "A major strength is our 12 years of experience in performing exactly these types of studies with other live viral vaccine models."
Mayo Clinic's resources as a genomics research center will also be integral in the effort. Genotyping of genomic DNA will be performed by the Mayo Genotyping Share Resource (GSR), a core laboratory under the direction of co-investigator Julie Cunningham, Ph.D. Other aspects of the research including bioinformatics -- the processing of the huge number of data points in this type of genomic research -- will involve Mayo biostatisticians and the Mayo Advanced Genomics Technology Center (AGTC).
"This award to Dr. Poland is another tangible confirmation that Mayo is fast becoming a leader in applying the tools of Genomics to the most pressing issues in the prevention, diagnosis and treatment of disease," said Eric Wieben, Ph.D., Director of the Mayo Genomics Research Center. The center is responsible for developing the AGTC.
The smallpox vaccine investigation is to begin immediately.
To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. MayoClinic.com (www.mayoclinic.com) is available as a resource for your health stories. For more information about research at Mayo Clinic, go to www.mayo.edu/research.